Zhitong Finance App News, WuWu Biology (300357.SZ) issued an announcement. Recently, the company downloaded and obtained the “Drug Clinical Trial Approval Notice” from the China Drug Administration's government service portal, and the S01D drug clinical trial application submitted by the company was approved. This drug is intended to treat drug-resistant tuberculosis in adults. The clinical trial application for this drug has been approved, and it is an important research and development node of the company in the field of anti-drug-resistant tuberculosis drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.